The company plans to use some of the funds to support development of a kinase inhibitor in Phase I testing for BCR-ABL fusion-positive chronic myeloid leukemia.

The drug is already approved for KMT2A-rearranged AML, and Syndax is hoping for approval in NPM1-mutated disease by the end of the year.

Studies doing genome-wide testing can easily ID patients with naturally low neutrophil counts, but nobody's looking at it, ...

The biotech, known as the developer of the first CRISPR drug, will consolidate sites in the state as it stops developing a diabetes cell therapy.

The agency approved a perioperative Keytruda regimen based on a 30 percent reduction in the risk of recurrence, progression, or death versus the control arm.

NEW YORK – Artera said this week that it has received a laboratory permit from New York State allowing it to offer its artificial intelligence-based prostate cancer test to patients there. The ...

The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

NEW YORK – Philochem, a Swiss subsidiary of Philogen, announced this week that it will license worldwide rights for its lead radiopharmaceutical to RayzeBio, which is owned by Bristol Myers Squibb.

Medical ethicists are bringing attention to an early chapter of precision medicine history, an often overlooked aspect of an ...

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.